30. Mai 2013

Hornig & al., accepted in Cancer Immunology

Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy

article accepted in Cancer Immunology, Immunotherapy

Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy

Nora Hornig, Katharina Reinhardt, Vanessa Kermer, Roland E. Kontermann, Dafne Müller

Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany.

Abstract:
Combinatory strategies are becoming of increasing interest in cancer immunotherapy. Costimulation by individual members of the immunoglobulin-like (Ig)- and TNF superfamily have already shown promising antitumor potential, thus prompting the exploration of their synergistic abilities in combinatorial approaches. Here, we pursued a targeted strategy with antibody-fusion proteins composed of a tumor-directed antibody and the extracellular domain of the costimulatory ligand B7.1, 4-1BBL, OX40L, GITRL or LIGHT, respectively. Costimulatory activity was assessed in an experimental setting where initial T cell activation was induced by a bispecific antibody (tumor-related antigen × CD3). Advantage of combined targeted costimulation was shown for either B7.1 or 4-1BBL with OX40L, GITRL, LIGHT and 4-1BBL in terms of T cell proliferation and IFN-γ release. Since encouraging results were obtained by the combination of B7.1 and 4-1BBL, we adapted the model system for a time-shift setting. Here, enhanced proliferation and granzyme B expression as well as reduced PD-1 expression on the T cell population demonstrated the benefit of costimulation-assisted restimulation. Finally, the antitumor potential of this combinatorial setting was confirmed in vivo in a lung metastasis mouse model. Thus, combinatorial approaches with costimulatory antibody–ligand fusion proteins seem a promising strategy to be further investigated for cancer immunotherapy.

Links
Zum Seitenanfang